Acusphere AI-700 Imaging Agent Phase III Protocols Expected By Early 2002
Acusphere plans to submit Phase III protocols for its ultrasound contrast agent AI-700 to FDA by early 2002.
You may also be interested in...
DuPont Pharmaceuticals will support an autumn launch of its Definity echocardiography ultrasound contrast agent with a user training program.
Ivax has started shipping its generic version of Bristol's injectable anti-tumor agent Taxol (paclitaxel), Ivax President Neil Flanzraich told the CIBC World Markets Healthcare Conference in New York City Oct. 25.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011